Friday, September 18, 2026
60 articles analyzed
Updated Sep 18, 8:35 PM · 60 sources analyzed
Key Takeaways
Abivax's two Phase 3 UC trials are complete in the registry, but zero efficacy data are public — the readout timing is now the key catalyst.
GSK quietly terminated its Phase 2 IPF program for GSK3915393 with no rationale disclosed, adding to the long list of fibrosis program failures.
MoonLake, Crinetics, and Beckley Psytech each completed Phase 2 studies today with no data released — watch for medical meeting disclosures in late 2026 to early 2027.
🏆 Winner
Crinetics Pharmaceuticals — Phase 2 TouCAHn study completion advances atumelnant toward a potential Phase 3 go decision in congenital adrenal hyperplasia, a validated commercial opportunity.
📉 Loser
GlaxoSmithKline — quiet termination of a Phase 2 IPF program signals another pipeline setback in a disease area the company has invested in without consistent success.
🔭 Watch Next
Abivax's ABTECT-1 and ABTECT-2 topline data release — potentially at UEG Week in October 2026 — will be the most consequential readout visible in today's sources, setting the stage for a potential NDA filing in ulcerative colitis.
Abivax Phase 3 UC trials reach completion in registry
Abivax's ABTECT-1 and ABTECT-2, two Phase 3 randomized placebo-controlled trials evaluating ABX464 (obefazimod) in moderately-to-severely active ulcerative colitis, have both been marked Completed on ClinicalTrials.gov. No efficacy or safety data have been released alongside these registry updates, leaving investors without the numbers needed to assess whether the drug can compete in a crowded UC market. The readout, whenever it arrives, will face a high bar: approved biologics and JAK inhibitors already hold strong positions in this indication, and Abivax will need to show clinically meaningful remission rates — not just statistical significance — to justify a commercial path forward.
ClinicalTrials.gov ↗Abivax S.A.
ABX464 (obefazimod) in Ulcerative Colitis (moderately to severely active)
ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) are both marked Completed on ClinicalTrials.gov as of 2026-09-18. The studies were randomized, placebo-controlled trials evaluating ABX464 25 mg or 50 mg once daily for induction of clinical remission. Full efficacy and safety data have not yet been released alongside the registry status update.
Why it matters
Registry completion without accompanying data is a holding pattern, not a catalyst — the key question is whether Abivax releases topline results at a near-term medical meeting such as UEG Week or ECCO, and whether remission rates at the 50 mg dose are differentiated enough to justify entering a market where Pfizer's etrasimod and AbbVie's upadacitinib already have entrenched positions. Until numbers are public, the investment thesis rests entirely on execution.
What to watch
Watch for Abivax to announce topline ABTECT data at UEG Week (October 2026) or in a separate press release — the 50 mg dose induction remission rate versus placebo will be the decisive figure.
Apnimed
AD109 in Obstructive Sleep Apnea (OSA)
The SynAIRgy Study (NCT05813275), a 6-month randomized double-blind placebo-controlled Phase 3 parallel-arm trial comparing a fixed-dose combination of AD109 to placebo in OSA, is now marked Completed on ClinicalTrials.gov. No efficacy or safety outcomes have been disclosed alongside the registry status change.
Why it matters
Apnimed is privately held and has been quiet on data, which makes the registry completion notable as a signal that a readout is imminent. The competitive dynamic is real: Eli Lilly's tirzepatide has shown OSA benefit in obese patients, narrowing the addressable population for a non-GLP-1 oral mechanism, so Apnimed's efficacy data will need to show benefit in a broad OSA population to maintain a differentiated story.
What to watch
Watch for Apnimed to release SynAIRgy topline data or present at SLEEP 2027 or ATS 2027 — the primary AHI reduction endpoint versus placebo will determine whether this asset attracts pharma partnership interest.
MoonLake Immunotherapeutics AG
Sonelokimab in Hidradenitis Suppurativa (moderate to severe) and Psoriatic Arthritis
Two Phase 2 studies evaluating sonelokimab — one in active psoriatic arthritis (NCT05640245) and one in moderate-to-severe hidradenitis suppurativa (NCT05322473) — are both marked Completed on ClinicalTrials.gov. No efficacy or safety data have been disclosed alongside these registry status updates.
Why it matters
Having two Phase 2 studies simultaneously reach completion is operationally meaningful for a small-cap company — MoonLake's valuation is almost entirely predicated on sonelokimab's differentiation over secukinumab and ixekizumab, and the HS dataset in particular is closely watched given the high unmet need and bimekilimab competition from Alumis. Investors need the ACR and HiSCR response numbers before updating models.
What to watch
Watch for MoonLake to present Phase 2 data from both indications at EULAR 2027 or the European HS Conference — the HiSCR50 response rate in HS versus placebo is the most commercially consequential figure.
Beckley Psytech Limited
BPL-003 in Treatment-Resistant Depression (TRD)
A randomized, quadruple-masked, multi-center Phase 2 trial with open-label extension evaluating the efficacy and safety of BPL-003 in treatment-resistant depression (NCT05870540) is now marked Completed on ClinicalTrials.gov. No efficacy or safety outcomes have been disclosed alongside the registry status change.
Why it matters
Beckley Psytech is developing BPL-003 as a shorter-duration psychedelic experience than psilocybin, targeting a more practical clinical workflow — the Phase 2 completion comes at a critical moment when the field needs to demonstrate that the regulatory failures of MDMA-assisted therapy were mechanism-specific, not class-wide. The data will be closely read for both efficacy magnitude on depression rating scales and safety signals that regulators can accept.
What to watch
Watch for Beckley Psytech to present BPL-003 Phase 2 data at a psychiatric congress such as ACNP in December 2026 — the MADRS score change from baseline versus placebo will be the pivotal figure for Phase 3 go/no-go decisions.
ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) are both marked Completed on ClinicalTrials.gov as of 2026-09-18. The studies were randomized, placebo-controlled trials evaluating ABX464 25 mg or 50 mg once daily for induction of clinical remission. Full efficacy and safety data have not yet been released alongside the registry status update.
Why it matters
Completion of two pivotal UC trials positions Abivax for a potential NDA/MAA filing, but the lack of disclosed data means investors cannot yet model the commercial opportunity or assess competitive positioning against established therapies.
Analysis
Registry completion without accompanying data is a holding pattern, not a catalyst — the key question is whether Abivax releases topline results at a near-term medical meeting such as UEG Week or ECCO, and whether remission rates at the 50 mg dose are differentiated enough to justify entering a market where Pfizer's etrasimod and AbbVie's upadacitinib already have entrenched positions. Until numbers are public, the investment thesis rests entirely on execution.
What to watch
Watch for Abivax to announce topline ABTECT data at UEG Week (October 2026) or in a separate press release — the 50 mg dose induction remission rate versus placebo will be the decisive figure.
The SynAIRgy Study (NCT05813275), a 6-month randomized double-blind placebo-controlled Phase 3 parallel-arm trial comparing a fixed-dose combination of AD109 to placebo in OSA, is now marked Completed on ClinicalTrials.gov. No efficacy or safety outcomes have been disclosed alongside the registry status change.
Why it matters
OSA remains a largely pharmacologically underserved condition — if AD109 demonstrates meaningful AHI (apnea-hypopnea index) reduction, it could represent the first oral drug approved specifically for OSA, a market where CPAP compliance failures create substantial unmet need.
Analysis
Apnimed is privately held and has been quiet on data, which makes the registry completion notable as a signal that a readout is imminent. The competitive dynamic is real: Eli Lilly's tirzepatide has shown OSA benefit in obese patients, narrowing the addressable population for a non-GLP-1 oral mechanism, so Apnimed's efficacy data will need to show benefit in a broad OSA population to maintain a differentiated story.
What to watch
Watch for Apnimed to release SynAIRgy topline data or present at SLEEP 2027 or ATS 2027 — the primary AHI reduction endpoint versus placebo will determine whether this asset attracts pharma partnership interest.
Two Phase 2 studies evaluating sonelokimab — one in active psoriatic arthritis (NCT05640245) and one in moderate-to-severe hidradenitis suppurativa (NCT05322473) — are both marked Completed on ClinicalTrials.gov. No efficacy or safety data have been disclosed alongside these registry status updates.
Why it matters
MoonLake's pipeline hinges on demonstrating that its tri-specific nanobody targeting IL-17A, IL-17F, and albumin can outperform approved IL-17A-only inhibitors in inflammatory diseases; completion of both studies signals that Phase 3-enabling data packages are likely being assembled.
Analysis
Having two Phase 2 studies simultaneously reach completion is operationally meaningful for a small-cap company — MoonLake's valuation is almost entirely predicated on sonelokimab's differentiation over secukinumab and ixekizumab, and the HS dataset in particular is closely watched given the high unmet need and bimekilimab competition from Alumis. Investors need the ACR and HiSCR response numbers before updating models.
What to watch
Watch for MoonLake to present Phase 2 data from both indications at EULAR 2027 or the European HS Conference — the HiSCR50 response rate in HS versus placebo is the most commercially consequential figure.
A randomized, quadruple-masked, multi-center Phase 2 trial with open-label extension evaluating the efficacy and safety of BPL-003 in treatment-resistant depression (NCT05870540) is now marked Completed on ClinicalTrials.gov. No efficacy or safety outcomes have been disclosed alongside the registry status change.
Why it matters
The psychedelic-assisted therapy space is crowded and facing regulatory headwinds following MDMA's CRL; a clean Phase 2 efficacy signal in TRD would give BPL-003 a credible path to Phase 3 in a high-value indication with enormous unmet need.
Analysis
Beckley Psytech is developing BPL-003 as a shorter-duration psychedelic experience than psilocybin, targeting a more practical clinical workflow — the Phase 2 completion comes at a critical moment when the field needs to demonstrate that the regulatory failures of MDMA-assisted therapy were mechanism-specific, not class-wide. The data will be closely read for both efficacy magnitude on depression rating scales and safety signals that regulators can accept.
What to watch
Watch for Beckley Psytech to present BPL-003 Phase 2 data at a psychiatric congress such as ACNP in December 2026 — the MADRS score change from baseline versus placebo will be the pivotal figure for Phase 3 go/no-go decisions.
The TouCAHn Phase 2 open-label sequential dose cohort study (NCT05907291) evaluating atumelnant's safety, efficacy, and pharmacokinetics in classic congenital adrenal hyperplasia is now marked Completed on ClinicalTrials.gov. No efficacy or safety data have been disclosed alongside this registry update.
Why it matters
Crinetics is competing directly with Spruce Biosciences and Neurocrine in the CAH space — Phase 2 data from TouCAHn will help define whether atumelnant's ACTH receptor antagonist mechanism can match the androgen-reduction benchmarks set by tildacerfont.
Analysis
Crinetics already has paltusotide approved in acromegaly, giving the company commercial credibility, but atumelnant in CAH is a distinct mechanism play that will live or die on androstenedione suppression data relative to competitors — investors will want to see whether the open-label design yielded a clean enough efficacy signal to support a randomized Phase 3 design that the FDA will accept. The absence of interim disclosures during the study is notable.
What to watch
Watch for Crinetics to present TouCAHn results at ENDO 2027 or release topline data by Q1 2027, with particular attention to androstenedione and 17-OHP (17-hydroxyprogesterone, a key biomarker of adrenal overactivity) suppression versus baseline.
Non-invasive ALT kinetics as a proxy for liver necrosis extent in acetaminophen toxicity
A preprint from bioRxiv describes a mathematical modeling approach that uses the kinetics of circulating alanine aminotransferase (ALT, a liver enzyme released into the blood when liver cells die) over time to quantitatively estimate the extent of hepatic necrosis in acetaminophen-treated mice without requiring tissue biopsy at each timepoint.
Why it matters
If validated in humans, this approach could reduce the number of animals needed in preclinical hepatotoxicity studies and provide a non-invasive, serially sampled biomarker framework for real-time liver injury monitoring in early clinical trials of drugs with hepatotoxicity risk.
Analysis
Drug developers running first-in-human studies for hepatotoxic compounds have long faced the challenge that ALT alone is a lagging and noisy signal — a kinetic modeling framework that extracts structural information about injury magnitude from the ALT curve could change how dose-escalation safety monitoring committees interpret liver signals and make stopping decisions. This is preclinical work in mice and will require significant translational validation before influencing clinical practice.
What to watch
Watch for a follow-up publication testing this ALT kinetics model in human acetaminophen overdose cohorts or drug-induced liver injury (DILI) registries, which would be the key step toward clinical applicability.
FFA2 receptor modulates neutrophil NADPH oxidase activity downstream of formyl peptide receptors
A bioRxiv preprint demonstrates that free fatty acid receptor 2 (FFA2R), a G protein-coupled receptor expressed on neutrophils, regulates the activation of NADPH oxidase (an enzyme complex that generates reactive oxygen species, a key part of the inflammatory response) triggered by formyl peptide receptor agonists, suggesting crosstalk between metabolic sensing and innate immune activation pathways.
Why it matters
FFA2R is already a target of interest for gut inflammation given its role in short-chain fatty acid signaling; demonstrating that it also gates neutrophil oxidative burst activity in a receptor-specific manner opens a potential avenue for anti-inflammatory compounds that could modulate both metabolic and immune pathways without broadly suppressing neutrophil function.
Analysis
This is early mechanistic biology and does not yet translate to a drug target in the conventional sense, but it adds specificity to the FFA2R biology that could interest companies developing gut-restricted or systemic anti-inflammatory programs — particularly those working in IBD or neutrophil-driven lung diseases where oxidative burst contributes to tissue damage. The receptor-level selectivity between FPR1 and FPR2 pathways is the detail worth tracking as the field develops more selective FFA2R agonists.
What to watch
Watch for follow-up studies testing selective FFA2R agonists in in vivo inflammation models — particularly in neutrophilic lung disease or IBD — to determine whether this receptor crosstalk has therapeutic leverage at the tissue level.
GlaxoSmithKline terminates Phase 2 IPF program for GSK3915393
A ClinicalTrials.gov update shows that GSK's Phase 2 study of GSK3915393 in idiopathic pulmonary fibrosis (a fatal scarring lung disease with limited treatment options) has been marked Terminated, with no explanation or efficacy data disclosed in the registry entry.
Why it matters
IPF remains a fiercely competitive and scientifically difficult indication where multiple mechanisms have failed to improve on the modest but established efficacy of nintedanib and pirfenidone — a Phase 2 termination without disclosed rationale adds to the list of attrition in this space and may inform the field about which biological targets are proving difficult to prosecute.
Analysis
GSK has been selectively pruning its respiratory pipeline in favor of programs with clearer differentiation, and a Phase 2 termination in IPF — regardless of the reason — signals that GSK3915393 did not clear the internal bar. For investors watching the IPF space, this keeps the competitive field defined by nintedanib (Boehringer), pirfenidone generics, and emerging entrants like inhaled treprostinil and TGFB-targeted agents. The mechanism of GSK3915393 was not widely disclosed publicly, making it difficult to draw broad lessons without further information from GSK.
What to watch
Watch for GSK to clarify the reason for termination — safety, futility, or strategic reprioritization — in a future investor presentation or pipeline update, as the answer has different implications for the broader IPF target landscape.
Motric Bio
Motric Bio terminates Phase 2 trial of MTR-601 in cervical dystonia (a neurological condition causing involuntary neck muscle contractions), with no efficacy data or reason disclosed in the ClinicalTrials.gov registry.
Why it matters
Cervical dystonia has limited oral treatment options beyond botulinum toxin injections, and a Phase 2 termination for MTR-601 — an 8-week randomized placebo-controlled study — narrows the field of emerging oral alternatives for patients who are poor candidates for or resistant to botulinum toxin.
Analysis
Motric Bio is a small, relatively unknown company, and the termination of its only visible clinical program is a meaningful setback for its pipeline. Without a disclosed reason, it is impossible to distinguish between a safety signal, enrollment failure, or investor-driven wind-down — but any of those outcomes leaves the company with a significantly more uncertain near-term outlook.
What to watch
Watch for Motric Bio to issue a public statement clarifying the reason for trial termination and whether any salvageable data from enrolled patients will be analyzed or published.
Synairgen Research Ltd.
Synairgen terminates Phase 2 study of inhaled SNG001 (interferon-beta-1a) in mechanically ventilated patients with respiratory viral infection, according to a ClinicalTrials.gov registry update with no efficacy data or rationale disclosed.
Why it matters
SNG001 had previously shown mixed signals in COVID-19 hospitalized patients, and a termination in the more severe mechanically ventilated population — where antiviral benefit is hardest to demonstrate — likely closes off this particular development path for inhaled interferon in critical illness.
Analysis
Synairgen's SNG001 program has had a difficult history: an early COVID-19 signal that did not hold up in larger trials, and now a terminated study in the most severe patients. This termination, combined with the general retreat of the antiviral respiratory field since the COVID-19 era, raises questions about whether inhaled interferon-beta has a viable commercial pathway without a clear patient selection strategy and a pandemic-scale enrollment opportunity.
What to watch
Watch for Synairgen to announce whether any remaining SNG001 development paths — such as non-mechanically ventilated hospital patients or specific viral subtypes — remain in their pipeline plans, or whether the asset is being deprioritized entirely.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.
Every weekday morning
Start your morning with the stories moving biotech.
Clinical readouts · FDA watch · Deal flow · Pipeline pulse